CO2021015998A2 - Materiales y métodos para modular la inmunidad mediada por células t - Google Patents

Materiales y métodos para modular la inmunidad mediada por células t

Info

Publication number
CO2021015998A2
CO2021015998A2 CONC2021/0015998A CO2021015998A CO2021015998A2 CO 2021015998 A2 CO2021015998 A2 CO 2021015998A2 CO 2021015998 A CO2021015998 A CO 2021015998A CO 2021015998 A2 CO2021015998 A2 CO 2021015998A2
Authority
CO
Colombia
Prior art keywords
methods
modulating
materials
antibodies
cell mediated
Prior art date
Application number
CONC2021/0015998A
Other languages
English (en)
Inventor
Rajkumar Ganesan
Sanjaya Singh
Iqbal S Grewal
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CO2021015998A2 publication Critical patent/CO2021015998A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos anti-TRGV9 o fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y métodos para usar los anticuerpos para tratar o prevenir enfermedades, tales como el cáncer.
CONC2021/0015998A 2019-05-08 2021-11-26 Materiales y métodos para modular la inmunidad mediada por células t CO2021015998A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962844966P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
US201962844959P 2019-05-08 2019-05-08
US201962844976P 2019-05-08 2019-05-08
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Publications (1)

Publication Number Publication Date
CO2021015998A2 true CO2021015998A2 (es) 2021-12-10

Family

ID=73051172

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0015998A CO2021015998A2 (es) 2019-05-08 2021-11-26 Materiales y métodos para modular la inmunidad mediada por células t

Country Status (21)

Country Link
US (2) US11667712B2 (es)
EP (1) EP3965818A4 (es)
JP (1) JP2022533538A (es)
KR (1) KR20220017892A (es)
CN (1) CN113966231A (es)
AU (1) AU2020267504A1 (es)
BR (1) BR112021022089A2 (es)
CA (1) CA3139508A1 (es)
CL (1) CL2021002905A1 (es)
CO (1) CO2021015998A2 (es)
CR (1) CR20210548A (es)
DO (1) DOP2021000229A (es)
EC (1) ECSP21087921A (es)
IL (1) IL287817A (es)
JO (1) JOP20210297A1 (es)
MA (1) MA55903A (es)
MX (1) MX2021013532A (es)
PE (1) PE20220763A1 (es)
SG (1) SG11202112021QA (es)
TW (1) TW202108618A (es)
WO (1) WO2020227457A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
WO2022180271A1 (en) 2021-02-26 2022-09-01 LAVA Therapeutics N.V. Antibodies that bind CD123 and gamma-delta T cell receptors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2467738A1 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
IN2012DN02485A (es) * 2009-09-03 2015-08-28 Hoffmann La Roche
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
JP2013537414A (ja) 2010-08-05 2013-10-03 アナプティスバイオ インコーポレイティッド Ｉｌ−１７に対する抗体
CN108341868B (zh) 2010-11-05 2022-06-07 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
HUE038225T2 (hu) 2011-08-23 2018-10-29 Roche Glycart Ag Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák
HRP20211773T1 (hr) 2011-11-04 2022-03-04 Zymeworks Inc. Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
BR112014015018A2 (pt) 2011-12-19 2020-10-27 Synimmune Gmbh moléculas de anticorpo biespecífico e seu método de produção, bem como composição farmacêutica e molécula de ácido nucleico
US9907820B2 (en) * 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
KR102359264B1 (ko) 2014-04-10 2022-02-04 라바 테라퓨틱스 비.브이. 인간 Vγ9Vδ2 T 세포에 결합하는 면역글로불린
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
CN110536901B (zh) 2016-12-26 2024-06-18 协和麒麟株式会社 与髓鞘少突胶质细胞糖蛋白结合的抗体
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
EP3743081A4 (en) 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
MX2022010664A (es) 2020-02-27 2022-11-30 Janssen Biotech Inc Materiales y métodos para modular una respuesta inmunitaria.
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
TW202233674A (zh) 2020-10-28 2022-09-01 美商健生生物科技公司 用於調節δγ鏈介導之免疫的組成物及方法

Also Published As

Publication number Publication date
CL2021002905A1 (es) 2022-06-17
PE20220763A1 (es) 2022-05-16
EP3965818A4 (en) 2023-05-31
JOP20210297A1 (ar) 2023-01-30
AU2020267504A1 (en) 2021-12-02
WO2020227457A1 (en) 2020-11-12
CN113966231A (zh) 2022-01-21
IL287817A (en) 2022-01-01
US20240150464A1 (en) 2024-05-09
CR20210548A (es) 2022-02-11
BR112021022089A2 (pt) 2022-02-08
KR20220017892A (ko) 2022-02-14
EP3965818A1 (en) 2022-03-16
JP2022533538A (ja) 2022-07-25
ECSP21087921A (es) 2022-01-31
US20210032338A1 (en) 2021-02-04
DOP2021000229A (es) 2022-07-31
TW202108618A (zh) 2021-03-01
US11667712B2 (en) 2023-06-06
CA3139508A1 (en) 2020-11-12
MX2021013532A (es) 2022-02-11
MA55903A (fr) 2022-03-16
SG11202112021QA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
BR112021020629A2 (pt) Compostos bicíclicos
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
CO2022004694A2 (es) Heterociclos bicíclicos como inhibidores de fgfr
CO2021015998A2 (es) Materiales y métodos para modular la inmunidad mediada por células t
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
UY39416A (es) Moléculas de direccionamiento inmunes multiespecíficas y usos de estas
CO2018010827A2 (es) Anticuerpos anti-factor bb del complemento y usos de estos
CL2022002766A1 (es) Anticuerpos anti-phf-pau y sus usos.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
EA202190807A1 (ru) Антитела к синуклеину
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
UY39699A (es) Anticuerpos anti-tau y usos de estos
UY39415A (es) Métodos y composiciones para modular la inmunidad mediada por cadenas beta
EA202092122A1 (ru) Антитела против tip-1 и их применения
UY39127A (es) Materiales y métodos para modular la inmunidad mediada por cadena delta
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками
AR115424A1 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33 / anti-cd3 y usos de estos
EA202092121A1 (ru) Антитела против cd73 и их применения
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
ECSP22020678A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares